FOLLOW THE LEADERS: HOW TO IDENTIFY, ENGAGE, AND LEVERAGE EXPERT OPINIONS IN RARE DISEASE
Orphan diseases present their own unique challenges that further complicate drug development. If bringing the right drug to the right patient is the goal, and providing high quality information is the path to achieving that goal, how can orphan drug developers ensure that education is created, shaped, and directed in the most effective way?
KOLs Are the Key
Key opinion leaders (KOLs) are physicians who have the requisite clinical expertise, scientific knowledge, and/or depth of understanding to optimize a product’s lifecycle. Proper identification, engagement and utilization of KOL resources can help orphan drug developers overcome the challenges inherent to their markets.
About Arcus Medica
Based in Philadelphia, Arcus Medica pairs extensive pharmaceutical industry and academic experience with rare disease agency expertise to seamlessly translate clinical and scientific data into meaningful content. Together with our KOL expert consultants, we can establish the right clinical foundation and context needed to support your call to action.
- What are the three challenges that face orphan drug development?
- How are KOLs identified?
- How can a company best utilize KOL input?
Whitepaper by: Mary Seideman, MD, PhD
We are thrilled to announce that Arcus Medica are joining us as a sponsor at this year’s World Orphan Drug Congress USA 2016. Register today to meet them in D.C. on April 20-22.